

1           **UV1 cancer vaccine in pembrolizumab-treated patients with recurrent or**  
2           **metastatic PD-L1 positive head and neck squamous cell carcinoma: results**  
3           **from the randomized phase 2 FOCUS trial**  
4

5 Anna Brandt<sup>1</sup>, Konrad Klinghammer<sup>2</sup>, Christoph Schultheiss<sup>1,3</sup>, Lisa Paschold<sup>4</sup>,  
6 Claudia Wickenhauser<sup>5</sup>, Marcus Bauer<sup>5</sup>, Anna Bergqvist<sup>6</sup>, Dennis Hahn<sup>7</sup>, Philippe  
7 Schafhausen<sup>8</sup>, Mareike Tometten<sup>9</sup>, Markus Blaurock<sup>10</sup>, Henrike Barbara Zech<sup>11</sup>, Chia-  
8 Jung Busch<sup>10</sup>, Andreas Dietz<sup>12</sup>, Urs Müller-Richter<sup>13</sup>, Jürgen Alt<sup>14</sup>, Andreas Boehm<sup>15</sup>,  
9 Simone Kowoll<sup>16</sup>, Jörg Steighardt<sup>16</sup>, Alexander Lasch<sup>16</sup>, Ingunn Hagen Westgaard<sup>6</sup>,  
10 Marita Westhrin<sup>6</sup>, Alexander Stein<sup>17</sup>, Axel Hinke<sup>18</sup>, Mascha Binder<sup>1,3</sup>

11  
12 **Affiliations**

13 <sup>1</sup> Division of Medical Oncology, University Hospital Basel, Basel, Switzerland

14 <sup>2</sup> Department of Hematology and Oncology, Campus Benjamin Franklin, Charité -  
15 Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-  
16 Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

17 <sup>3</sup> Laboratory of Translational Immuno-Oncology, Department of Biomedicine,  
18 University and University Hospital Basel, Basel, Switzerland

19 <sup>4</sup> Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University  
20 Halle-Wittenberg, Halle (Saale), Germany

21 <sup>5</sup> Institute of Pathology, University Hospital Halle, Martin-Luther-University Halle-  
22 Wittenberg, Halle (Saale), Germany

23 <sup>6</sup> Ultimovacs ASA, Oslo, Norway

24 <sup>7</sup> Klinikum Stuttgart, Stuttgart, Germany; Dept. of Hematology, Oncology, Stem-Cell  
25 Transplantation and Palliative Care

26 <sup>8</sup> Department of Oncology, Hematology and Bone Marrow Transplantation with  
27 Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg,  
28 Germany

29 <sup>9</sup> Department of Hematology, Oncology, Hemostaseology and Stem Cell  
30 Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany

31 <sup>10</sup> Department of Otorhinolaryngology, Head and Neck Surgery, University Medicine  
32 Greifswald, Greifswald, Germany

33 <sup>11</sup> Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf,  
34 **Hamburg, Germany**

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

35 <sup>12</sup> Department of Otolaryngology, Head and Neck Surgery, University of Leipzig,  
36 Leipzig, Germany

37 <sup>13</sup> University Hospital Würzburg, Bavarian Cancer Research Center (BZKF),  
38 Würzburg, Germany

39 <sup>14</sup> Department of Internal Medicine III (Hematology, Oncology), University Medical  
40 Center Mainz, Mainz, Germany

41 <sup>15</sup> Department of Otorhinolaryngology, St. Georg Hospital, Leipzig, Germany

42 <sup>16</sup> Coordination Center for Clinical Trials, Medical Faculty, Martin-Luther-University  
43 Halle-Wittenberg, Halle (Saale), Germany

44 <sup>17</sup> Hematology-Oncology Practice Eppendorf (HOPE), Hamburg, Germany

45 <sup>18</sup> Clinical Cancer Research Consulting (CCRC), Düsseldorf, Germany

46

47 **Funding:** The trial including translational research was funded by a research grant  
48 from ULTIMOVACS.

49

50 **Corresponding author:** Mascha Binder, Medical Oncology, University Hospital  
51 Basel, Switzerland, [mascha.binder@usb.de](mailto:mascha.binder@usb.de)

52

53 **Running title:** UV1 vaccination in head and neck cancer

54

55 **Key words:** UV1, pembrolizumab, head and neck cancer

56

57 **Conflicts of interest:**

58 Mascha Binder received institutional research grants from Merck, BMS, Hexal,  
59 Novartis, German Cancer Aid (Krebshilfe), German Research Foundation and the  
60 Federal Ministry of Education and Research as well as honoraria for lectures and  
61 advisory board meetings by Celgene, Janssen, Gilead, Merck, Roche, Amgen, Sanofi-  
62 Aventis and BMS. She received funding for the FOCUS trial from ULTIMOVACS.

63 Alexander Stein received research funding from MSD and serves as an advisory board  
64 member for MSD. Urs Müller-Richter serves as a consultant or advisor and/or received  
65 honoraria from AstraZeneca, BioNTech, BMS, KuraOncology, Merck, MSD, Novartis,  
66 and Sanofi. Jürgen Alt serves as an advisor for AstraZeneca, MSD, Novartis, Roche,  
67 BMS, Janssen, and Merck and received honoraria from AstraZeneca, BMS, Roche,  
68 and Boehringer Ingelheim. Konrad Klinghammer serves as a consultant or advisor  
69 and/or received honoraria from MSD, Merck, BMS, Roche, Novartis, Sanofi, Bayer,  
70 BioNTech, Boehringer Ingelheim, and onkowissen. Anna Brandt received honoraria  
71 from Merck. Dennis Hahn serves as a consultant or advisor and/or received honoraria  
72 from BMS, MSD and Merck. Henrike Barbara Zech serves as a consultant and /or  
73 received honoraria from MSD, Merck, BMS, Sanofi, Regeneron. Chia-Jung Busch  
74 received institutional research grants from BMS and German Cancer Aid (Krebshilfe)  
75 as well as honoraria for lectures and advisory board meetings by Bayer, BMS, GSK,  
76 Merck, MSD, Sanofi-Aventis. Ingunn Hagen Westgaard, Anna Bergqvist and Marita  
77 Westrin are employed by Ultimovacs ASA. Philippe Schafhausen serves as a  
78 consultant or advisor and/or received honoraria from Alexion, AOP Orphan  
79 Pharmaceutical, Blueprint Medicines, GSK, MSD, Merck, BMS, Novartis, Pfizer,  
80 Roche, Sanofi, and Sobi. All other authors declare no potential conflict of interest.

81

82

83 **Abstract**

84 Background: Human telomerase reverse transcriptase (hTERT) is highly expressed  
85 (75-100%) in head and neck squamous cell carcinoma (HNSCC). The FOCUS study  
86 examines the role of the hTERT-directed vaccine UV1 in combination with  
87 pembrolizumab in patients with recurrent or metastatic (R/M) HNSCC.

88 Methods: The FOCUS trial, a two-armed, open-label, non-comparative, randomized,  
89 multicenter phase 2 study, was designed to assess the efficacy and feasibility of UV1  
90 as an add-on to pembrolizumab in the first-line treatment of patients with R/M PD-L1  
91 positive HNSCC. A progression-free survival rate at 6 months (PFSR@6) of 40% was  
92 deemed promising for further development in a phase 3 setting. The trial was  
93 conducted in 10 centers in Germany.

94 Results: From August 2021 to July 2023, 25 patients were enrolled in the calibration  
95 arm A and 50 patients in the UV1 arm B. Median age was 65 years and 18% of patients  
96 had an ECOG performance score of 2. The PFSR@6 was 30% in the UV1 arm. No  
97 specific safety signals were observed in the UV1 arm apart from a reversible allergic  
98 reaction that appeared in one patient. At a median follow-up of almost one year (11.3  
99 months), median overall survival was 13.1 months in the calibration arm A and 12.6  
100 months in the UV1 arm B. Clinical trial identification number NCT05075122.

101 Conclusions: The addition of UV1 to pembrolizumab was safe but did not show an  
102 efficacy signal in this study population.

103

104

## 105 **Introduction**

106 Head and neck squamous cell carcinoma (HNSCC) ranks as the seventh most  
107 prevalent cancer globally and is linked to tobacco use, alcohol consumption, and  
108 human papillomavirus (HPV) infection in oropharyngeal cancer (1, 2). Initial-stage  
109 therapy aims for a cure, yet more than half of HNSCC patients experience recurrent  
110 and/or metastatic (R/M) disease despite aggressive multimodal approaches (3). Many  
111 patients with R/M HNSCC qualify solely for palliative systemic therapy (4).

112 The incorporation of the epidermal growth factor receptor (EGFR) antibody cetuximab  
113 into platinum and fluorouracil (EXTREME regimen) substantially increased overall  
114 survival from 7.4 to 10.1 months as first-line treatment for R/M HNSCC, becoming the  
115 standard in 2008 (4, 5). More recently, the FDA approved pembrolizumab, a  
116 programmed death 1 (PD-1) immune checkpoint inhibitor, for first-line treatment based  
117 on the KEYNOTE-048 trial. Pembrolizumab with chemotherapy demonstrated  
118 improved overall survival compared to cetuximab with chemotherapy (median 13.0 vs.  
119 10.7 months) (6). Particularly in patients with PD-L1 Combined Positive Score (CPS)  
120  $\geq 1$  and CPS  $\geq 20$ , pembrolizumab alone outperformed cetuximab with chemotherapy,  
121 underscoring increased efficacy with higher PD-L1 expression (7).

122 Despite durable responses in some patients, the majority (85-95%) of R/M HNSCC  
123 patients exhibit either no response or short-term benefit to immune checkpoint  
124 inhibitors (3). Insufficient T cell effector response might contribute to this lack of  
125 response (8). Efforts to enhance T cell response involve investigating therapeutic  
126 cancer vaccines, such as UV1, targeting human telomerase reverse transcriptase  
127 (hTERT), a key player in carcinogenesis activated in 85-90% of cancers (8-12). UV1  
128 induced persistent immune responses lasting up to 7.5 years in phase I trials in  
129 patients with advanced melanoma, non-small cell lung cancer and prostate cancer,

130 with promising results when combined with checkpoint inhibitors in the melanoma  
131 patients (8).

132 In HNSCC, where high hTERT expression (75-100%) is prevalent (13), the FOCUS  
133 trial (14) sought to evaluate the effectiveness of UV1 vaccination combined with  
134 pembrolizumab versus pembrolizumab alone in patients with PD-L1 positive R/M  
135 HNSCC.

136 **Results**

137 *Disposition of study patients*

138 **Table 1: Patient disposition and categories of evaluability (CONSORT)**

Parameter	Arm A	Arm B	Total
Randomised patients	26	52	78
Non-eligible for analysis (major primary protocol violation), randomised	-	2*	2*
No data available, randomised	1**	-	1**
Full analysis population (ITT) for this report***	25	50	75
Evaluability (ITT) with respect to			
Tumor response (iRECIST) at end of protocol treatment	22	45	67***
Progression-free survival (PFS)	25	50	75
<b>PFS rate at 6 months (primary endpoint)</b>	25	50	75
Overall survival (OS)	25	50	75
Evaluability for safety	25	50	75

139  
140 \* Two patients were excluded due to severe violation of entry criteria, present at randomization:  
141 performance status too poor (ECOG >2) and required antibiotic treatment; no protocol therapy applied.  
142 \*\* Informed consent withdrawn one day after randomization; no protocol therapy applied. \*\*\* With a  
143 valid iRECIST re-staging.

144  
145  
146 Recruitment started in August 2021 and was closed in July 2023. Data base lock was  
147 July 24th, 2024. A total of 78 patients from a total of ten different study sites were  
148 randomized (Table 1). At its final closure, the database included information on 75  
149 randomized, evaluable patients, 25 in arm A (calibration arm, pembrolizumab alone)  
150 and 50 in arm B (experimental arm, pembrolizumab and UV1 vaccination), forming the  
151 ITT full analysis set (Table 1). One patient did not receive the first protocol-defined  
152 pembrolizumab cycle and was excluded from the per-protocol (PP) population.

153

154

155 *Baseline characteristics*

156 **Table 2: Baseline characteristics of eligible patients**

Parameter	Arm A	Arm B	Total
n	25	50	75
<b>Age</b>			
Mean $\pm$ SD	64.5 $\pm$ 11.3	67.5 $\pm$ 10.5	66.5 $\pm$ 10.8
<b>Sex</b>			
Female	7 (28%)	8 (16%)	15 (20%)
Male	18 (72%)	42 (84%)	60 (80%)
<b>ECOG</b>			
n	24	48	72*
ECOG 0	8 (33%)	17 (35%)	25 (35%)
ECOG 1	9 (38%)	24 (50%)	33 (46%)
ECOG 2	7 (29%)	6 (12%)	13 (18%)
ECOG 3	0 (0%)	1 (2%)**	1 (1%)**

157 \* The baseline vital sign visit was missing in 3 patients. \*\* Patient needing a wheelchair due to a non-  
158 oncological condition; accepted for inclusion by principal investigator; ECOG, Eastern Cooperative  
159 Oncology Group; n, number  
160

161 Age and gender were equally distributed among the study arms, with a slight tendency  
162 to more elderly and male patients in the experimental arm (Table 2). In contrast, there  
163 was a slight trend towards less favourable ECOG performance status in arm A (Table  
164 2).

165

166 *Disease status at recruitment*

167 Overall, clinical features were relatively well balanced between the arms. Most patients  
168 (fewer in arm B) entered the FOCUS trial due to relapsing disease (Table 3). While  
169 advanced stages of the primary tumor were slightly more frequent in the UV1 arm B,  
170 more patients with distant metastases were randomised to arm A (Table 3). Distant



171 metastases were predominantly located in the lung (Table 3). Median PD-L1 CPS was  
172 35 (range 1-100) in arm A and 27 (range 1-100) in the UV1 arm B.

173

174 **Table 3: Disease status at recruitment**

Parameter	Arm A	Arm B	Total
<b>Disease status</b>			
n	25	50	75
Relapse	21 (84%)	34 (68%)	55 (73%)
Initial diagnosis	4 (16%)	16 (32%)	20 (27%)
<b>Stage</b>			
n	25	47	72
Stage I	-	1 (2%)	1 (1%)
Stage II	-	5 (11%)	5 (7%)
Stage III	1 (4%)	4 (9%)	5 (7%)
Stage IVa	6 (24%)	12 (26%)	18 (25%)
Stage IVb	6 (24%)	9 (19%)	15 (21%)
Stage IVc	12 (48%)	16 (34%)	28 (39%)
<b>Location of metastases</b>			
n	15	22	37
Bone	1 (7%)	2 (9%)	3 (8%)
Liver	4 (27%)	3 (14%)	7 (19%)
Lung	8 (53%)	12 (55%)	20 (54%)
Skin	2 (13%)	1 (5%)	3 (8%)
Other	4 (27%)	6 (27%)	10 (27%)
<b>Pre-treatment</b>			
n	25	50	75
Surgery	13 (52%)	29 (58%)	42 (56%)
Adjuvant radiotherapy	3 (12%)	7 (14%)	10 (13%)
Adjuvant chemoradiotherapy	8 (32%)	20 (40%)	28 (37%)

Definitive chemoradiotherapy	3 (12%)	8 (16%)	11 (15%)
Radiotherapy	5 (20%)	7 (14%)	12 (16%)
Other	2 (8%)	3 (6%)	5 (7%)

175

176 *Antineoplastic treatment and duration of follow-up*

177 Median duration of pembrolizumab treatment was 15.1 weeks (range 0.1-98.6) in arm  
178 A versus 12.1 weeks (range 0-84.3) in arm B. Median number of UV1 administrations  
179 per patient was 8 (range 1-8). About half of the patients (54%) received the maximum  
180 number of vaccine administrations.

181 Mean duration of follow-up since randomization was slightly shorter than one year  
182 (11.3 months), ranging up to 28.7 months, and was quite similar in both study arms  
183 (11.7 months in arm A and 11.1 months in arm B).

184

185 *Tumor response*

186 **Table 4: Response at the end of protocol therapy**

Category	Arm A	Arm B	Total
n	22	45	67
CR	3 (14%)	2 (4%)	5 (7%)
PR	7 (32%)	8 (18%)	15 (22%)
SD	1 (5%)	6 (13%)	7 (10%)
PD unconfirmed	4 (18%)	12 (27%)	16 (24%)
PD confirmed	7 (32%)	17 (38%)	24 (36%)

187

188 Tumor response according to iRECIST as investigated at the end of protocol therapy,  
189 is shown in Table 4. A total of 67 out of 75 patients had a valid restaging result at this  
190 time point. The corresponding overall response rate (CR + PR = ORR) was 45% in  
191 arm A (95% CI, 24%-68%) and 22% in arm B (95% CI, 11%-37%) (p = 0.086).

192 *Progression-free survival*

193 The results for the primary endpoint of the study, i.e. the crude proportion of patients  
194 surviving without progression at 6 months after randomization, are shown in Table 5.  
195 With respect to the formal study hypothesis, the two-sided 80% CI (corresponding to  
196 the 90% one-sided CI as relevant for superiority) of the rate in the experimental arm B  
197 does not exclude the 25% boundary, which was pre-defined as futility threshold.  
198 Moreover, the 40% finding in the group treated with pembrolizumab alone (arm A) is  
199 higher than expected. Thus, a positive signal for the experimental treatment cannot be  
200 derived from the results of this phase 2 study.

201

202 **Table 5: Crude PFS rate at 6 months (primary endpoint)**


Parameter	Arm A	Arm B
n	25	50
Number of patients surviving free from progression at 6 months	10	15
Crude rate	40%	30%
Exact 95% CI	21%-61%	18%-45%
Exact 90% CI	24%-58%	19%-42%
Exact 80% CI	27%-55%	21%-40%

203

204 Correspondingly, the Kaplan-Meier estimation of progression-free survival (PFS) from  
205 the time point of randomization (Figure 1A), based on a total of 63 observed PFS  
206 events in the ITT population of 75 patients (84%), shows no major difference between  
207 the arms. The medians in arm A and B are similar with 3.9 (95% CI, 3.0-13.1) and 3.3  
208 months (95% CI, 3.2-4.4), respectively. The 6-month PFS rates estimated according  
209 to Kaplan-Meier are 42% (95% CI, 26%-67%) and 31% (95% CI, 20%-47%),

210 respectively. The hazard ratio (HR) amounts to 1.3 (95% CI, 0.76-2.23) suggesting no  
211 relevant difference between the arms.

212 The Kaplan-Meier estimation of overall survival (OS) from the time point of  
213 randomization, based on a total of 46 observed deaths in the ITT population of 75  
214 patients (61%) is provided in Figure 1B. The medians in arm A and B were similar with  
215 13.1 (95% CI, 7.7-undefined) and 12.6 months (95% CI, 9.5-19.6), respectively. The  
216 hazard ratio amounts to 1.22 (95% CI: 0.64-2.32).



217

218 **Figure 1. Efficacy of UV1 + pembrolizumab treatment in patients with R/M HNSCC. A,** Kaplan-  
219 Meier estimates of progression-free survival. **B,** Kaplan-Meier estimates of overall survival.

220

## 221 Safety

222 The safety analysis is based on the total population of 75 patients. A total of 61 grade  
223 3 or higher adverse events (AEs) were recorded in the ITT population, 44% of patients  
224 in arm A and 50% in arm B experienced at least one such AE. Table 6 presents an  
225 overview of observed adverse events, overall and according to severity and other pre-  
226 defined categories. No relevant differences between the two study arms were  
227 detected.

228

229

230 **Table 6: Overview of adverse events**

Parameter	Arm A	Arm B
n	25	50
Total number of adverse events reported	124	263
Number of adverse events of severity grade 3 to 5	21	40
Number of patients with any adverse event	25 (100%)	47 (94%)
Number of patients with any adverse event of severity grade 3 to 5	11 (44%)	25 (50%)
Number of patients with any serious AE (SAE)	10 (40%)	28 (56%)
Number of patients with any AE of special interest	NA	1 (2%)*

231 \*Severe anaphylactic reaction

232

233 Grade 3 or higher AEs are summarized in Table 7.

234 **Table 7. Patients experiencing grade 3 or higher adverse events**


Adverse event	Arm A n=25	Arm B n=50
Infection	5 (20%)	7 (14%)
Sepsis	1 (4%)	0
Lipase increased	0	1 (2%)
Abdominal pain	0	1 (2%)
Diarrhea	0	1 (2%)*
Allergic reaction	0	1 (2%)

235 \*Grade missing

236

237 *hTERT tissue expression*

238 hTERT tissue expression at baseline was assessed in 63 patients. There was a trend  
239 to longer progression free survival with hTERT expression >0 in arm B, however, this  
240 trend was also seen in the control arm A (Figure 2).




241

242 **Figure 2.** Kaplan-Meier estimates of progression-free survival of patients with hTERT expression >0  
243 and 0 in arm A (A), and arm B (B).  
244

### 245 *Immune response to UV1*

246 To assess UV1-specific T cell responses over time, IFN- $\gamma$  secretion was quantified via  
247 ELISPOT assays after stimulation of patient-derived peripheral blood mononuclear  
248 cells (PBMCs) obtained at visit 1 (baseline, BL) and follow-up (FU) timepoints (visit 6  
249 and/or end of treatment (EOT)/progressive disease (PD)) with UV1 vaccine peptides  
250 (p719-20, p728, p725 or the UV1 peptide pool). As shown in Figure 3, individual  
251 patients in both study arms displayed UV1-directed T cell responses at baseline.  
252 Notably, UV1-directed T cell responses were almost undetectable in the FU time  
253 points in arm A without vaccination (Figure 3). UV1-directed T cell responses were  
254 observed in 12 of 14 vaccinated individuals (Figure 3, arm B). The highest reactivity  
255 was detected after stimulation with the UV1 peptide pool or the p719-20 peptide, while  
256 reactivity to the single hTERT peptides p728 and p725 was substantially lower (Figure  
257 3).

258



259

260

261 **Figure 3: Quantification of pre- and post-vaccination immune responses to UV1.** UV1-directed T  
262 cell responses were quantified using IFN- $\gamma$  ELISPOT after peptide stimulation of patient derived  
263 PBMCs. Mean ELISPOT counts per patient are shown for both arms. Sample numbers in arm A: BL  
264 n=4, FU n=5; arm B: BL n=16, FU n=13. BL sampled at visit 1, FU sampled at visit 6 and/or end of  
265 treatment (EOT)/progressive disease (PD). UV1 refers to hTERT peptide mix (=UV1 vaccine)  
266 encompassing the peptides p719-20 (hTERT amino acids 660-689, peptide 728 (hTERT amino acids  
267 651-665) and peptide 725 (hTERT amino acids 691-705).

268

## 269 Discussion

270 The treatment of advanced or recurrent head and neck cancer remains a significant  
271 challenge. Current treatment options, such as chemotherapy and immunotherapy are  
272 established treatment options albeit with limited efficacy (5, 6, 15). Moreover, most  
273 pivotal trials excluded more frail patients who are likely to experience severe side  
274 effects and have poorer overall outcomes (16). Therefore, trial results are often not  
275 representative for patients with head and neck cancer many of which suffering from  
276 concomitant medical conditions (17). Safe and at the same time effective treatment  
277 options that spare toxicities in these frail patients would represent a significant  
278 advancement.

279 To address these unmet needs, we conducted a phase 2 trial evaluating the hTERT  
280 vaccine UV1 in combination with pembrolizumab in a cohort of patients with advanced  
281 head and neck cancer. We enrolled patients up to an ECOG performance status of 2.  
282 Unfortunately, our findings indicate that the hTERT vaccine UV1 did not demonstrate  
283 a signal of efficacy in this population.

284 Our results stand in contrast to those of previous studies using the same vaccine in  
285 other cancers, such as melanoma, where more consistent immune responses were  
286 observed (8). In the recently published NIPU-trial a positive overall survival signal was  
287 observed in mesothelioma patients when UV1 was combined with ipilimumab and  
288 nivolumab (18). This discrepancy suggests that the immune environment and tumor  
289 biology of head and neck cancers may differ significantly from other tumor types,  
290 thereby influencing the efficacy of immunotherapeutic approaches such as UV1.

291 Despite these disappointing results, our study provides valuable insights into the  
292 efficacy of pembrolizumab in a more real-world patient population. In contrast to the  
293 KEYNOTE-048 trial, which limited the inclusion criteria to an ECOG of 1 due to the  
294 possible administration of additional chemotherapy, the FOCUS trial enrolled patients  
295 with an ECOG up to 2, made possible by exclusive use of pembrolizumab (6). In this  
296 frailer patient population overall response rate, progression-free survival and overall  
297 survival with pembrolizumab were comparable to the outcomes of PD-L1 positive  
298 patients in the KEYNOTE-048 trial (19). Recently, the results of the randomized phase  
299 3 trial ELAN UNFIT have been published, which compared the efficacy and safety of  
300 cetuximab to methotrexate in older, frail patients with R/M HNSCC (16). Even though  
301 this trial did not show an improvement in failure-free survival with cetuximab versus  
302 methotrexate, more trials such as ELAN UNFIT or FOCUS are needed to better



303 understand the unique therapeutic challenges and needs of older patients with head  
304 and neck cancer (20).

305 Moreover, our study contributes to the debate about the limitations of current  
306 immunotherapy approaches in advanced head and neck cancers. The lack of efficacy  
307 observed with the hTERT vaccine UV1 raises important questions about the role of  
308 telomerase-targeted immunotherapy in this setting and emphasizes the need for  
309 continued exploration of alternative strategies. Our results suggest that while  
310 telomerase-targeted immunotherapy holds promise for certain cancers, its application  
311 in head and neck cancers does not seem to be promising or would need other  
312 therapeutic modalities to enhance efficacy.

313

## 314 **Methods**

### 315 Clinical trial

316 Main inclusion criteria consisted of: Patients had to be at least 18 years of age, ECOG-  
317 performance score 0-2, with histologically confirmed diagnosis of non-resectable  
318 recurrent or metastatic head and neck squamous cell carcinoma with at least one  
319 measurable tumor lesion as per RECIST v.1.1. Patients had to be eligible for  
320 pembrolizumab monotherapy with a PD-L1 CPS  $\geq 1$  and adequate laboratory  
321 parameters. The trial was conducted at 10 centers in Germany in compliance with the  
322 Declaration of Helsinki. The study protocol was approved by the local ethics  
323 committees and authorized by the competent authority. All participants provided  
324 written informed consent. The trial is registered with ClinicalTrials.gov  
325 (NCT05075122).

326 Eligible patients were randomized to pembrolizumab mono (arm A) or pembrolizumab  
327 in combination with UV1 vaccination (arm B). Randomization was done via an online

328 tool (secuTrial®) of the Coordination Center for Clinical Trials, Medical Faculty, Martin-  
329 Luther-University Halle-Wittenberg, Halle (Saale), Germany. All patients received  
330 pembrolizumab until disease progression or up to two years. In Arm A patients  
331 received pembrolizumab 200 mg i.v. every 3 weeks, administration of pembrolizumab  
332 started in week 1 (treatment duration of 12 weeks). In arm B patients received  
333 pembrolizumab 200 mg i.v. every 3 weeks in combination with UV1 vaccination (300  
334 µg UV1 s.c. in addition to 75 µg GM-CSF s.c.). Three UV1 doses were applied during  
335 week 1, followed by 5 vaccinations every 3 weeks on day 1 of each cycle. In arm B  
336 administration of pembrolizumab started at week 2, one week later than in arm A  
337 (treatment duration of 13 weeks).

338 Radiological baseline assessment by computed tomography of the neck, chest,  
339 abdomen and pelvis not older than 4 weeks before randomization was performed.  
340 Patients were assessed on week 1, day 1 (visit 1), week 1, day 3 (visit 2), week 1, day  
341 5 (visit 3), week 2 (visit 4), week 5 (visit 5) week 8 (visit 6), week 11 (visit 7), week 14  
342 (visit 8), at the end of treatment (EOT), and at progressive disease (PD) if applicable.  
343 All patients were evaluated every 3 months after EOT until death or maximal 12  
344 months after last patient first visit.

345 The legal funder (sponsor) of the trial was the University Medical Center Halle (Saale),  
346 Germany.

347

#### 348 Statistical analysis

349 The primary endpoint was PFSR@6, defined as the proportion of patients alive without  
350 progression at six months after randomization divided by the total number of evaluable  
351 patients, and the low boundary of its one-sided 90% confidence interval,  
352 corresponding to a type I error level of 0.1. To detect a promising efficacy level of

353 PFSR@6  $\geq 40\%$  against a futility level of  $\leq 25\%$ , as expected for pembrolizumab single-  
354 agent treatment, with a power of 80%, 46 evaluable patients were required in the  
355 experimental arm (21). By 2:1 ratio, patients were allocated to a randomized reference  
356 arm, to allow some control of selection bias.

357 Due to the lack of adequate power, statistical comparisons between the study arms  
358 must be considered exploratory, with all p values being two-sided. Fisher's exact test  
359 was applied for nominal data, Student's t test for continuously distributed data, and the  
360 log rank test for time-to-event analysis, with hazard ratios derived from Cox models.

361

#### 362 Immunohistochemistry (IHC) for TERT

363 IHC staining was performed on a Bond III automated immunostainer (Leica  
364 Biosystems Nussloch GmbH, Wetzlar, Germany) using the Bond Polymer Refine  
365 Detection Kit (DS9800-CN). The polyclonal anti-TERT antibody (Telomerase catalytic  
366 subunit Antibody, 600-401-252, Rockland Immunochemicals Inc., Limerick, PA, USA)  
367 was applied in a dilution of 1:500. The staining intensity was scored using the H-score  
368 as described elsewhere (22).

369

#### 370 Quantification of anti-hTERT immune responses

371 PBMCs were seeded in 48-well plates at 6 million cells per well in IMDM medium  
372 (Gibco) supplemented with 10% heat-inactivated human serum,  
373 penicillin/streptomycin and 50  $\mu\text{M}$  beta-mercaptoethanol. The PBMCs were stimulated  
374 with UV1 drug product (peptide 725; hTERT 691-705 (RTFVLRVRAQDPPPE),  
375 peptide 719-20; hTERT 660-689 (ALFSVLNYERARRPGLLGASVLGLDDIHRA),  
376 peptide 728; hTERT 651-665 (AERLTSRVKALFSVL) (Corden Pharma, Caponago,  
377 Italy) at a concentration of 15  $\mu\text{M}$  each and 20  $\mu\text{g/ml}$  poly-ICLC (Oncovir). Medium

378 containing 20 U/ml IL-2 was replaced every two days. For IFN- $\gamma$  ELISPOT assays,  
379 cells were harvested on day 12, seeded as triplicates at 0.1 million each in ELISPOT  
380 plates (Human IFN- $\gamma$  ImmunoSpot, CTL). The UV1 peptides were added at 20  $\mu$ M  
381 each or 20  $\mu$ M UV1 peptide mix (= UV1 cancer vaccine). T cells alone served as  
382 negative control, T cells stimulated with 0.08 $\mu$ g/ml SEC-3 superantigen (Toxin  
383 Technology Inc. Sarasota, FL, USA) as positive control. Cells were incubated for 22  
384 hours before enumeration of the detected spots using an automated analyzer, CTL  
385 IMMUNOSPOT S5 VERSA-02-9030 (Cellular Technology Ltd, Shaker Heights, OH,  
386 USA). Specific spots were calculated by subtracting the mean number of spots  
387 detected in the medium-only control from the mean number of spots detected in the  
388 experimental samples.

### 389 **Contributors**

390 Concept and study design: MBI, AS, CJB, MW, JS, IHW, SK, AL, HBZ; Patient  
391 recruitment, data collection: KK, MBI, DH, PS, MT, MBI, JA, AD, UMR, ABo;  
392 Translational study design, molecular studies, data collection, data analysis, data  
393 interpretation: ABr, CS, LP, KK, CW, MBa, AH, MBI, MW, ABe, IHW; Statistical  
394 analysis: AH, LP; Drafting of the manuscript: ABr, MBI, CS. Critical revision of the  
395 manuscript for important intellectual content: all authors. All authors agreed to submit  
396 the manuscript and read and approved its content.

397

### 398 **Acknowledgements**

399 We thank all patients and families as well as all participating study centers.

400

401 **References**

- 402 1. M. Gormley, G. Creaney, A. Schache, K. Ingarfield, D. I. Conway, Reviewing the  
403 epidemiology of head and neck cancer: definitions, trends and risk factors. *Br Dent J*  
404 **233**, 780-786 (2022).
- 405 2. D. E. Johnson *et al.*, Head and neck squamous cell carcinoma. *Nat Rev Dis Primers*  
406 **6**, 92 (2020).
- 407 3. L. Q. M. Chow, Head and Neck Cancer. *N Engl J Med* **382**, 60-72 (2020).
- 408 4. A. Lau, W. F. Yang, K. Y. Li, Y. X. Su, Systemic Therapy in Recurrent or Metastatic  
409 Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-  
410 Analysis. *Crit Rev Oncol Hematol* **153**, 102984 (2020).
- 411 5. J. B. Vermorken *et al.*, Platinum-based chemotherapy plus cetuximab in head and  
412 neck cancer. *N Engl J Med* **359**, 1116-1127 (2008).
- 413 6. B. Burtneß *et al.*, Pembrolizumab alone or with chemotherapy versus cetuximab  
414 with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head  
415 and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. *Lancet* **394**,  
416 1915-1928 (2019).
- 417 7. B. Burtneß *et al.*, Pembrolizumab Alone or With Chemotherapy for  
418 Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048:  
419 Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. *J Clin*  
420 *Oncol* **40**, 2321-2332 (2022).
- 421 8. E. B. Ellingsen *et al.*, Durable and dynamic hTERT immune responses following  
422 vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three  
423 phase I clinical trials. *J Immunother Cancer* **10**, (2022).
- 424 9. S. Beyaert, J. P. Machiels, S. Schmitz, Vaccine-Based Immunotherapy for Head and  
425 Neck Cancers. *Cancers (Basel)* **13**, (2021).
- 426 10. C. B. Harley, Telomerase and cancer therapeutics. *Nat Rev Cancer* **8**, 167-179  
427 (2008).

- 428 11. A. N. Guterres, J. Villanueva, Targeting telomerase for cancer therapy. *Oncogene*  
429 **39**, 5811-5824 (2020).
- 430 12. N. W. Kim *et al.*, Specific association of human telomerase activity with immortal cells  
431 and cancer. *Science* **266**, 2011-2015 (1994).
- 432 13. A. Brandt, B. Thiele, C. Schultheiß, E. Daetwyler, M. Binder, Circulating Tumor DNA  
433 in Head and Neck Squamous Cell Carcinoma. *Cancers (Basel)* **15**, (2023).
- 434 14. A. Brandt *et al.*, Tolerability and efficacy of the cancer vaccine UV1 in patients with  
435 recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma  
436 planned for first-line treatment with pembrolizumab - the randomized phase 2  
437 FOCUS trial. *Front Oncol* **14**, 1283266 (2024).
- 438 15. J. Guigay *et al.*, Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil,  
439 and cetuximab as first-line treatment in patients with recurrent or metastatic head and  
440 neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-  
441 label, randomised, phase 2 trial. *Lancet Oncol* **22**, 463-475 (2021).
- 442 16. J. Guigay *et al.*, Cetuximab versus methotrexate in first-line treatment of older, frail  
443 patients with inoperable recurrent or metastatic head and neck cancer (ELAN  
444 UNFIT): a randomised, open-label, phase 3 trial. *Lancet Healthy Longev* **5**, e182-  
445 e193 (2024).
- 446 17. D. F. Eytan, A. L. Blackford, D. W. Eisele, C. Fakhry, Prevalence of Comorbidities  
447 among Older Head and Neck Cancer Survivors in the United States. *Otolaryngol*  
448 *Head Neck Surg* **160**, 85-92 (2019).
- 449 18. V. D. Haakensen *et al.*, UV1 telomerase vaccine with ipilimumab and nivolumab as  
450 second line treatment for pleural mesothelioma - A phase II randomised trial. *Eur J*  
451 *Cancer* **202**, 113973 (2024).
- 452 19. K. J. Harrington *et al.*, Pembrolizumab With or Without Chemotherapy in Recurrent or  
453 Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase  
454 III KEYNOTE-048 Study. *J Clin Oncol* **41**, 790-802 (2023).

- 455 20. L. L. Matos, L. P. Kowalski, The need to include older patients with head and neck  
456 cancer in clinical trials. *Lancet Healthy Longev* **5**, e380-e381 (2024).
- 457 21. R. P. A'Hern, Sample size tables for exact single-stage phase II designs. *Stat Med*  
458 **20**, 859-866 (2001).
- 459 22. B. Seliger *et al.*, Induction of pulmonary HLA-G expression by SARS-CoV-2 infection.  
460 *Cell Mol Life Sci* **79**, 582 (2022).
- 461